FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326611916> ?p ?o ?g. }

• W2326611916 endingPage "330" @default.
• W2326611916 startingPage "326" @default.
• W2326611916 abstract "Rationale and Objectives: The purpose of this study was to evaluate whether “steady state” magnetic resonance imaging (MRI) using a robust multiecho ΔR2* MR relaxometry technique is suitable for the early assessment of a clinically approved antiangiogenic treatment regimen using bevacizumab (Avastin). Methods: A673 rhabdomyosarcoma-bearing mice were treated with bevacizumab (n = 6) or saline as control, respectively (n = 6). MRI using a multigradient echo sequence was performed before and after 2 doses of 100 μg bevacizumab at baseline and day 7. Ultrasmall superparamagnetic iron oxide particles (SH U 555 C) induced changes of the transverse relaxation rate R2* (ΔR2*) were measured in regions of interest. From these results, the vascular volume fraction was estimated, providing a surrogate marker for the microvessel density (MVD). The actual MVD was determined by immunohistochemistry and correlated with the MRI results. Results: Bevacizumab treatment resulted in a significant reduction of the ΔR2* values compared with the control group (bevacizumab: 10.47 ± 0.78 seconds−1 vs. control: 17.91 ± 2.63 seconds−1; P = 0.01), reflecting the significant decrease of the vascular volume fraction by 33% (bevacizumab: 2.21% ± 0.15% vs. control: 3.31% ± 0.22%; P = 0.001). Immunohistochemistry confirmed the MR results showing an approximately 25% reduction of the MVD after treatment (bevacizumab: 7.11 ± 0.3 vs. control: 9.45 ± 0.38; P = 0.001). Conclusion: Multiecho ΔR2* MR relaxometry allows an early and quantitative assessment of tumor vascularization changes in response to an antiangiogenic treatment with a clinically approved vascular endothelial growth factor inhibitor. With the availability of long circulating ultrasmall superparamagnetic iron oxide particles s for clinical use, this imaging technique could be instantly translated to antiangiogenic treatment monitoring in clinical studies." @default.
• W2326611916 created "2016-06-24" @default.
• W2326611916 creator A5004237083 @default.
• W2326611916 creator A5009831302 @default.
• W2326611916 creator A5014839908 @default.
• W2326611916 creator A5022954978 @default.
• W2326611916 creator A5043595375 @default.
• W2326611916 creator A5054157987 @default.
• W2326611916 date "2011-05-01" @default.
• W2326611916 modified "2023-10-16" @default.
• W2326611916 title "Monitoring of Bevacizumab-Induced Antiangiogenic Treatment Effects By “Steady State” Ultrasmall Superparamagnetic Iron Oxide Particles Magnetic Resonance Imaging Using Robust Multiecho ΔR2* Relaxometry" @default.
• W2326611916 cites W1965882263 @default.
• W2326611916 cites W1966228017 @default.
• W2326611916 cites W1971428475 @default.
• W2326611916 cites W1975854184 @default.
• W2326611916 cites W1982574363 @default.
• W2326611916 cites W1983569280 @default.
• W2326611916 cites W1984582737 @default.
• W2326611916 cites W1985466440 @default.
• W2326611916 cites W1990990856 @default.
• W2326611916 cites W1993247096 @default.
• W2326611916 cites W1997972192 @default.
• W2326611916 cites W1999553818 @default.
• W2326611916 cites W2006202974 @default.
• W2326611916 cites W2011239315 @default.
• W2326611916 cites W2011843899 @default.
• W2326611916 cites W2019540655 @default.
• W2326611916 cites W2027493983 @default.
• W2326611916 cites W2036913456 @default.
• W2326611916 cites W2066135588 @default.
• W2326611916 cites W2075640066 @default.
• W2326611916 cites W2081633887 @default.
• W2326611916 cites W2083775147 @default.
• W2326611916 cites W2099998343 @default.
• W2326611916 cites W2104139707 @default.
• W2326611916 cites W2107108336 @default.
• W2326611916 cites W2109041633 @default.
• W2326611916 cites W2109606826 @default.
• W2326611916 cites W2124726866 @default.
• W2326611916 cites W2138132115 @default.
• W2326611916 cites W2141851994 @default.
• W2326611916 cites W2158261463 @default.
• W2326611916 cites W2161532329 @default.
• W2326611916 cites W2319962899 @default.
• W2326611916 cites W4251087695 @default.
• W2326611916 doi "https://doi.org/10.1097/rli.0b013e3182045457" @default.
• W2326611916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21358548" @default.
• W2326611916 hasPublicationYear "2011" @default.
• W2326611916 type Work @default.
• W2326611916 sameAs 2326611916 @default.
• W2326611916 citedByCount "7" @default.
• W2326611916 countsByYear W23266119162012 @default.
• W2326611916 countsByYear W23266119162014 @default.
• W2326611916 countsByYear W23266119162015 @default.
• W2326611916 countsByYear W23266119162016 @default.
• W2326611916 countsByYear W23266119162022 @default.
• W2326611916 crossrefType "journal-article" @default.
• W2326611916 hasAuthorship W2326611916A5004237083 @default.
• W2326611916 hasAuthorship W2326611916A5009831302 @default.
• W2326611916 hasAuthorship W2326611916A5014839908 @default.
• W2326611916 hasAuthorship W2326611916A5022954978 @default.
• W2326611916 hasAuthorship W2326611916A5043595375 @default.
• W2326611916 hasAuthorship W2326611916A5054157987 @default.
• W2326611916 hasConcept C126322002 @default.
• W2326611916 hasConcept C126838900 @default.
• W2326611916 hasConcept C142724271 @default.
• W2326611916 hasConcept C143409427 @default.
• W2326611916 hasConcept C2776694085 @default.
• W2326611916 hasConcept C2777802072 @default.
• W2326611916 hasConcept C2909801847 @default.
• W2326611916 hasConcept C2989005 @default.
• W2326611916 hasConcept C71924100 @default.
• W2326611916 hasConcept C73286259 @default.
• W2326611916 hasConcept C83042744 @default.
• W2326611916 hasConceptScore W2326611916C126322002 @default.
• W2326611916 hasConceptScore W2326611916C126838900 @default.
• W2326611916 hasConceptScore W2326611916C142724271 @default.
• W2326611916 hasConceptScore W2326611916C143409427 @default.
• W2326611916 hasConceptScore W2326611916C2776694085 @default.
• W2326611916 hasConceptScore W2326611916C2777802072 @default.
• W2326611916 hasConceptScore W2326611916C2909801847 @default.
• W2326611916 hasConceptScore W2326611916C2989005 @default.
• W2326611916 hasConceptScore W2326611916C71924100 @default.
• W2326611916 hasConceptScore W2326611916C73286259 @default.
• W2326611916 hasConceptScore W2326611916C83042744 @default.
• W2326611916 hasIssue "5" @default.
• W2326611916 hasLocation W23266119161 @default.
• W2326611916 hasLocation W23266119162 @default.
• W2326611916 hasOpenAccess W2326611916 @default.
• W2326611916 hasPrimaryLocation W23266119161 @default.
• W2326611916 hasRelatedWork W1619857359 @default.
• W2326611916 hasRelatedWork W1992848513 @default.
• W2326611916 hasRelatedWork W2078742082 @default.
• W2326611916 hasRelatedWork W2326611916 @default.
• W2326611916 hasRelatedWork W2607015440 @default.
• W2326611916 hasRelatedWork W2765367036 @default.
• W2326611916 hasRelatedWork W2914349912 @default.
• W2326611916 hasRelatedWork W4238549103 @default.

• next